A study by Vij R et al. [348] demonstrated that a single intravenous administration of autologous AD-MSCs significantly improved joint function in RA patients and, to some extent, reduced the levels of the inflammatory marker C-reactive protein (CRP). The gene discussed is CRP; the disease is rheumatoid arthritis.